China reveals 2009 results of regulatory measures
This article was originally published in SRA
A summary of drug review activities by China’s State Food and Drug Administration in 2009 has signalled that measures by the agency to tighten its control of drugs and enhance and facilitate the regulatory review of products are producing positive results. Neena Brizmohun reports from the 46th Annual Meeting of the Drug Information Association in Washington, DC, from 13-17 June.
You may also be interested in...
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.
New medicines under evaluation at the European Medicines Agency.
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.